This Program Project Grant focuses on development of novel, effective therapies for CML, based upon its molecular pathophysiology and its unique susceptibility to biologic therapies, allotransplantation and immunotherapeutic approaches. This program has been highly productive, with continuous funding for the last 19 years. The program is reorganized with 2 new projects in the competitive renewal to address the major issues and therapeutic opportunities in this field. This is a highly integrated program of 6 projects and 5 cores are proposed forming a comprehensive translational research program with investigation spanning the basic biology of CML to human clinical trials. This amended application is extensively revised to address the critique of the review. Project 3 from the A1 application is deleted and the projects are renumbered. Projects 1 and 2 involve clinical investigations translating scientific advances from the projects into human clinical trials designed to increase the rate of molecular complete remission and disease free survival in CML. Project 1 studies chemo-biologic therapies assessing tyrosine kinase inhibitors, antigen specific immunotherapy and hypomethylating therapy designed to overcome imatinib resistance. Project 2 involves novel strategies for hematopoietic transplantation focusing on enhancement of graft-vs-leukemia and antigen specific cellular immunotherapy against PR1, post transplant hypomethylating therapy and chemosensitization by interference with interaction of SDF-1 and CXCR4 to improve the therapeutic index. . Project 3 examines the interaction ofthe microenvironment and CML, and potential therapeutic interventions to interfere with these interactions. Project 4 evaluates the mechanisms of resistance to tyrosine kinase inhibitors in CML stem cells and potential therapeutic interventions to circumvent resistance. Project 5 examines molecular mechanisms of bcr-abl oncogenesis secreted cell death factors, lipocalins, and signaling through Jak-2. Project 6 examines the epigenome in CML, including Predictive and prognostic testing of selected epigenetic markers and pharmacodynamic analysis of epigenetic parameters in patients treated with hypomethylating therapies. Five cores are included: Core A is the administrative core. Core B is biostatistics. Core C provides cell culture and clonogenic assays. Core D is the cell collection and distribution core. Core E is the GMP Cell Laboratory and Immune Assessment Core, required for cell processing for human clinical trials and immune assessments required for these studies and the research projects. This is a productive, highly integrated program for development of novel therapies for CML.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-24
Application #
8722319
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Program Officer
Merritt, William D
Project Start
1997-02-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
24
Fiscal Year
2014
Total Cost
$3,477,908
Indirect Cost
$1,172,061
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Qazilbash, M H; Wieder, E; Thall, P F et al. (2016) PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia :
Jain, Preetesh; Kantarjian, Hagop; Sasaki, Koji et al. (2016) Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol 173:114-26
Tripathi, Satyendra C; Peters, Haley L; Taguchi, Ayumu et al. (2016) Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A 113:E1555-64
Andreeff, Michael; Kelly, Kevin R; Yee, Karen et al. (2016) Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res 22:868-76
Jain, Preetesh; Kantarjian, Hagop; Patel, Keyur P et al. (2016) Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127:1269-75
Chen, Z; Cortes, J E; Jorgensen, J L et al. (2016) Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 30:1606-9
Hoehn, Daniela; Cortes, Jorge E; Medeiros, L Jeffrey et al. (2016) Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S86-92
Lee, Dean A; Denman, Cecele J; Rondon, Gabriela et al. (2016) Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant 22:1290-8
Cortes, Jorge E; Lipton, Jeffrey H; Miller, Carole B et al. (2016) Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clin Lymphoma Myeloma Leuk 16:286-96
Khorashad, J S; Tantravahi, S K; Yan, D et al. (2016) Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia 30:2275-2279

Showing the most recent 10 out of 325 publications